NDLI: Telmisartan for the reduction of cardiovascular morbidity and mortality.

Please wait, while we are loading the content...

Year: 2017 Volume: 10

Year: 2016 Volume: 9

Year: 2015 Volume: 8

Year: 2014 Volume: 7

Year: 2013 Volume: 6

Year: 2012 Volume: 5

Year: 2011 Volume: 4

Year: 2011 Volume: 4 Issue: 6

Year: 2011 Volume: 4 Issue: 5

Year: 2011 Volume: 4 Issue: 4

Year: 2011 Volume: 4 Issue: 3

Year: 2011 Volume: 4 Issue: 2

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Regulation of appetite to treat obesity.

Corticosteroids in brain cancer patients: benefits and pitfalls.

G-quadruplexes: selective DNA targeting for cancer therapeutics?

Optimal timing of antiretroviral therapy initiation in patients coinfected with HIV and tuberculosis.

Telmisartan for the reduction of cardiovascular morbidity and mortality.

Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review.

Trazodone: properties and utility in multiple disorders.

Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension.

Found in translation: integrated approaches to drug development.

Green pharmacy and pharmEcovigilance: prescribing and the planet.

Modeling and predicting drug pharmacokinetics in patients with renal impairment.

Year: 2011 Volume: 4 Issue: 1

Year: 2010 Volume: 3

Year: 2009 Volume: 2

Year: 2008 Volume: 1

Telmisartan for the reduction of cardiovascular morbidity and mortality.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Verdecchia, Paolo Angeli, Fabio Gentile, Giorgio Mazzotta, Giovanni Reboldi, Gianpaolo
Description	Country affiliation: Italy Author Affiliation: Verdecchia P ( Unità Operativa Complessa di Medicina, Ospedale di Assisi, Via Valentin Muller, 06081 Assisi, Italy. verdec@tin.it)
Abstract	Cardiovascular disease (CVD) poses a significant healthcare and economic burden on societies and individuals. Angiotensin II is a key component of the renin-angiotensin system that plays a central role in atherosclerotic mechanisms that contribute to CVD. Renin-angiotensin system blockers are widely used to reduce cardiovascular (CV) risk owing to their potential both to lower blood pressure, a CV risk factor, and to attenuate the atherosclerotic disease process directly. Telmisartan has a number of pharmacological properties that distinguish it from other angiotensin II receptor blockers (ARBs) - the longest plasma half-life, highest lipophilicity and strongest receptor binding affinity in class. The ONTARGET(®) trial showed that telmisartan is as effective as ramipril in reducing CV morbidity (including myocardial infarction and stroke) and mortality in a broad range of patients at increased CV risk. Evidence from other ARBs remains largely restricted to patients with heart failure, diabetic nephropathy or specific subsets of hypertensive patients. Telmisartan is, therefore, the only ARB with a broad indication for CV risk reduction in patients with atherothrombotic disease or diabetes with end-organ damage.
File Format	HTM / HTML
ISSN	17512433
Issue Number	2
Volume Number	4
e-ISSN	17512441
Journal	Expert Review of Clinical Pharmacology
Language	English
Publisher	Taylor & Francis
Publisher Date	2011-03-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Angiotensin Ii Type 1 Receptor Blockers Therapeutic Use Angiotensin-converting Enzyme Inhibitors Benzimidazoles Benzoates Cardiovascular Diseases Drug Therapy Mortality Chemistry Animals Epidemiology Humans Morbidity Randomized Controlled Trials As Topic Methods Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology, Toxicology and Pharmaceutics Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in